➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:


Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,201,517

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,201,517 protect, and when does it expire?

Patent 10,201,517 protects MIRVASO and is included in one NDA.

This patent has thirty-four patent family members in twenty-six countries.

Summary for Patent: 10,201,517
Title:Brimonidine gel compositions and methods of use
Abstract: Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.
Inventor(s): Buge; Jean-Christophe (Nice, FR), Nadau Fourcade; Karine (Villeneuve Loubet, FR), Meunier; Cyril (St. Raphael, FR)
Assignee: Galderma Laboratories, L.P. (Fort Worth, TX)
Application Number:15/220,501
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

Drugs Protected by US Patent 10,201,517

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp MIRVASO brimonidine tartrate GEL;TOPICAL 204708-001 Aug 23, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,201,517

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France10 58612Oct 21, 2010

International Family Members for US Patent 10,201,517

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 083651   Start Trial
Australia 2011317554   Start Trial
Brazil 112013009578   Start Trial
Canada 2814952   Start Trial
China 103298451   Start Trial
Cyprus 1115683   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.